Amicus Therapeutics and GlaxoSmithKline Announce Top Line 6-Month Primary Treatment Period Results From First Phase 3 Fabry Monotherapy Study

[at noodls] – CRANBURY, N.J. and LONDON, Dec. 19, 2012 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq:FOLD) and GlaxoSmithKline plc (GSK) today announced the 6-month primary treatment period results from the first … more

View todays social media effects on FOLD

View the latest stocks trending across Twitter. Click to view dashboard

See who Amicus is hiring next, click here to view